Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Aesthet Surg J ; 37(7): 771-775, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28402493

ABSTRACT

The objective was to analyze and discuss the implications of a nonmalignant CD30+ late seroma. Methods included collection of seroma fluid and peripheral blood from a patient with a late seroma 22 years after initial breast reconstruction. A panel of 24 monoclonal antibodies was used to detect T-cell receptor Vß regions present on ~70% of normal human peripheral blood T lymphocytes. Flow cytometry gated on CD3+ and CD30+ activated T lymphocytes. Cytospins were used to inspect the morphology of the T lymphocytes. Results from the seroma fluid cytology revealed a spectrum of activated T lymphocytes as seen in the blood of patients with immune disorders such as infectious mononucleosis. Cells were judged to be nonmalignant by routine pathology. Flow cytometry revealed >23% of CD3+ T lymphocytes belonged to an expanded T-cell family expressing TCRVß13.2. Most Vß13.2 cells expressed T-cell activation antigen CD30 indicating that CD30 is not restricted to anaplastic large cell lymphoma (ALCL) in seroma fluids. A smaller expanded population of CD30+ T lymphocytes expressing TCRVß 13.2 was detected in the blood. In conclusion, in this index case, an expanded population of CD30+ activated T lymphocytes was detected in seroma fluid surrounding a textured breast implant as well as in peripheral blood, consistent with a local and systemic immune response. The demonstration of an expanded CD30+ T-cell population in a polyclonal background suggests a possible role for bacterial superantigens as a pathogenic factor. These data further suggest that breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) may be the end stage of a CD30+ T-cell lymphoproliferative disorder. LEVEL OF EVIDENCE: 5.


Subject(s)
Breast Implantation/adverse effects , Breast Implants/adverse effects , Breast Neoplasms/surgery , Ki-1 Antigen/metabolism , Lymphoma, Large-Cell, Anaplastic/diagnosis , Seroma/pathology , T-Lymphocytes/metabolism , Aged , Biofilms , Breast Implants/microbiology , Endoscopic Ultrasound-Guided Fine Needle Aspiration , Female , Flow Cytometry , Humans , Lymphoma, Large-Cell, Anaplastic/blood , Lymphoma, Large-Cell, Anaplastic/etiology , Seroma/blood , Seroma/immunology , T-Lymphocytes/immunology , Time Factors
2.
Spine (Phila Pa 1976) ; 38(12): E691-8, 2013 May 20.
Article in English | MEDLINE | ID: mdl-23429681

ABSTRACT

STUDY DESIGN: Prospective, randomized, controlled preclinical trial. OBJECTIVE: This study seeks to characterize the localized and systemic host response to recombinant human bone morphogenetic protein-2 (rhBMP-2) in a well established rodent spine arthrodesis model utilizing cytokine analysis and magnetic resonance imaging (MRI). SUMMARY OF BACKGROUND DATA: Although high fusion rates are achieved with rhBMP-2 in the spine, several complications have also been reported, including a localized response leading to radiculitis and seroma formation. The mechanism in which this occurs clinically is yet unknown. METHODS: One hundred female Fischer rats underwent a posterolateral intertransverse lumbar spinal fusion, with paraspinal muscle tissue resection, using iliac crest autograft, type I absorbable collagen sponge (ACS), 10- or 100-µg rhBMP-2/ACS. The animals underwent magnetic resonance imaging evaluation, serum cytokine analysis, manual palpation, and gross tissue inspection at 2, 4, 7, 10, and 21 days, postoperatively. RESULTS: Qualitative evaluation of MR images demonstrated a transient fluid collection at the surgery site in the rhBMP-2 animals as early as 4 and 7 days that was greater than the autograft or ACS groups. Quantitative analysis on T2-weighted axial images demonstrated greater signal intensity in the rhBMP-2 animals compared with the ACS and autograft groups in a time-dependent fashion. Higher concentrations of several cytokines were also detected at 2, 4, and 7 days, including interleukin 1ß, interleukin 18, tumor necrosis factor α, macrophage inflammatory protein 1α, and monocyte chemotactic protein 1 in animals treated with rhBMP-2/ACS relative to ACS alone. CONCLUSION: Our data suggest that the in vivo host response to rhBMP-2 in an animal model may be associated with circulating proinflammatory and osteoclastic cytokines.


Subject(s)
Bone Morphogenetic Protein 2/toxicity , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/surgery , Osteolysis/chemically induced , Seroma/chemically induced , Spinal Fusion , Animals , Autografts , Bone Morphogenetic Protein 2/administration & dosage , Bone Transplantation , Cytokines/blood , Female , Humans , Ilium/transplantation , Inflammation Mediators/blood , Lumbar Vertebrae/metabolism , Lumbar Vertebrae/pathology , Magnetic Resonance Imaging , Models, Animal , Osteolysis/blood , Rats, Inbred F344 , Recombinant Proteins/toxicity , Seroma/blood , Seroma/pathology , Spinal Fusion/adverse effects , Surgical Sponges , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...